Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptinyx Inc.

www.aptinyx.com

Latest From Aptinyx Inc.

Aptinyx Sees Path Forward In DPN With Long-Term Patients

After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.

Clinical Trials Business Strategies

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

Research & Development Clinical Trials

Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication

Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.

Neurology Research & Development

J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds

Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Naurex spin-off
  • Enarex Inc.
  • Eranix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Aptinyx Inc.
  • Senior Management
  • Norbert G Riedel, PhD, Pres. & CEO
    Ashish Khanna, CFO & CBO
    Joseph R Moskal, PhD, CSO
    Torsten M Madsen, MD, PhD, CMO
    Andrew Kidd, Chief Commercial Officer
    Cassia Cearley, PhD, VP, Research
    David R Houck, PhD, Chief Dev. Officer
  • Contact Info
  • Aptinyx Inc.
    Phone: (847) 871-0377
    909 Davis St.
    Ste. 600
    Evanston, IL 60201
    USA
UsernamePublicRestriction

Register